Apr 7, 2022
Natasha Drapeau is the Executive Vice President of BioSig Technologies, pioneers in advanced biomedical signal processing solutions that will unlock the future of bioelectronic medicine, starting with the PURE EP™ System and their work on common and complex cardiac arrhythmia. Approximately more than half of patients diagnosed with this heart rhythm disorder have AFib. The BioSig noninvasive technology works with all the systems generating data to get an entire cardiac picture for diagnosis and performing a cardiac ablation procedure.
Natasha explains, "What we're focusing on with our technology is really to prevent that signal distortion. That's happening both through our different hardware architecture and the software algorithms. We focus on delivering a much cleaner, more detailed cardiac picture displayed to the physician in real-time."
"But also, we're uncovering a lot of diagnostic data that was simply not there before. We have side-by-side comparisons because we have other technology in support at the same time as PURE EP. I believe we have an opportunity there to give that better, more comprehensive cardiac picture to physicians, and that could lead to a transformation of care."
@BioSig_Tech #MedTech #MedicalTechnology #AFib #AtrialFibrillation #AfibAwareness #Electrophysiology #Epeeps #GlobalEP #AF #Ablation #Cardiology #CardioTwitter #HeartHealth #BioelectronicMedicine
